MYNDSET
Commercial- Indications
- Obesity, Mental health
Company intelligence / Profile preview
MYND Therapeutics develops science-based, customer-centric digital therapies designed to prevent, treat, and manage chronic diseases such as obesity, diabetes, hypertension, depression, anxiety, and more. Their approach leverages innovative software experiences to deliver effective behavioral interventions with the goal of achieving outcomes comparable to drug therapies but with fewer side effects. The company aims for FDA approval of its core product as a prescribable therapy within an estimated timeframe of under two years from their last public update.[2][4]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MYND Therapeutics.